Literature DB >> 29265338

Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways.

Charithani B Keragala1, Dominik F Draxler1, Zoe K McQuilten2, Robert L Medcalf1.   

Abstract

Coagulation and innate immunity are linked evolutionary processes that orchestrate the host defence against invading pathogens and injury. The complement system is integral to innate immunity and shares numerous interactions with components of the haemostatic pathway, helping to maintain physiological equilibrium. The term 'immunothrombosis' was introduced in 2013 to embrace this process, and has become an area of much recent interest. What is less apparent in the literature however is an appreciation of the clinical manifestations of the coagulation-complement interaction and the consequences of dysregulation of either system, as seen in many inflammatory and thrombotic disease states, such as sepsis, trauma, atherosclerosis, antiphospholipid syndrome (APS), paroxysmal nocturnal haemoglobinuria (PNH) and some thrombotic microangiopathies to name a few. The growing appreciation of this immunothrombotic phenomenon will foster the drive for novel therapies in these disease states, including anticoagulants as immunomodulators and targeted molecular therapies.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  coagulation; complement; haemostasis; immunothrombosis; innate immunity

Mesh:

Substances:

Year:  2017        PMID: 29265338     DOI: 10.1111/bjh.15062

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  47 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

Review 2.  Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells.

Authors:  Melissa M Lee-Sundlov; Sean R Stowell; Karin M Hoffmeister
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

3.  Thrombosis of the Portal Vein and Superior Mesenteric Vein in a Patient With Subclinical COVID-19 Infection.

Authors:  Jasneet Randhawa; Jasveen Kaur; Harneet S Randhawa; Sifatpreet Kaur; Harinderpal Singh
Journal:  Cureus       Date:  2021-04-08

Review 4.  Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19.

Authors:  Lucas C Godoy; Ewan C Goligher; Patrick R Lawler; Arthur S Slutsky; Ryan Zarychanski
Journal:  CMAJ       Date:  2020-08-16       Impact factor: 8.262

Review 5.  COVID-19 associated thromboinflammation of renal capillary: potential mechanisms and treatment.

Authors:  Xiaojing Chen; Chengyuan Yu; Haijiao Jing; Chunxu Wang; Xinyi Zhao; Jinming Zhang; Shuoqi Zhang; Huan Liu; Rujuan Xie; Jialan Shi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

6.  Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome.

Authors:  Michelle Petri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Mitigating placental injuries through up-regulating DAF in experimental APS mice: new mechanism of progesterone.

Authors:  Y Zhang; S Jin
Journal:  Clin Exp Immunol       Date:  2019-06-20       Impact factor: 4.330

8.  Damage- and pathogen-associated molecular patterns play differential roles in late mortality after critical illness.

Authors:  John Eppensteiner; Jean Kwun; Uwe Scheuermann; Andrew Barbas; Alexander T Limkakeng; Maggie Kuchibhatla; Eric A Elster; Allan D Kirk; Jaewoo Lee
Journal:  JCI Insight       Date:  2019-08-22

Review 9.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

Review 10.  [Coagulation dysfunction in COVID-19].

Authors:  Yiming Xu; Dandan Lyu; Kejing Ying
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.